ClinicalTrials.gg
CompletedNCT01969838Simplify 1Updated May 12, 2023Results posted

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

A Phase 3 interventional study of Momelotinib and Ruxolitinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 114 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.

Enrollment
Largest of 12
432 · median 138
Started
2013
the only one that year
Phase 3
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
8 of 12
Sierra Oncology LLC - a GSK company

Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one has the largest enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 4th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About momelotinib

momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing momelotinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor).

Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 216 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those participants planning to continue treatment with MMB following the end of the study, the Early Study Drug Discontinuation (ESDD), 30-day, 12-Week, and survival follow-up visits are not required.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Palpable splenomegaly at least 5 cm below the left costal margin
  • Confirmed diagnosis of PMF or post-PV/ET MF
  • Requires myelofibrosis therapy, in the opinion of the investigator
  • Classified as high risk OR intermediate-2 risk as defined by the International Prognostic Scoring System (IPSS) for PMF, or intermediate-1 risk (IPSS) associated with symptomatic splenomegaly, hepatomegaly, anemia ( \< 10.0 g/dL), and/or unresponsive to available therapy
  • Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug:

    • (ANC) ≥ 0.75 x 10\^9/L in the absence of growth factor in the prior 7 days
    • Count ≥ 50 x 10\^9/L (≥ 100 x 10\^9/L if [AST] or alanine aminotransferase [ALT] is ≥ 2 x the [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days
    • Peripheral blood blast count \< 10%
    • AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days)
    • Calculated (CrCL) of ≥ 45 mL/min
    • Direct ≤ 2.0 x ULN
  • of > 24 weeks
  • Males and females of must agree to use protocol-specified method(s) of
  • Females who are nursing must agree to discontinue nursing before the first dose of study drug
  • Able to understand and willing to sign the form

Key Exclusion Criteria:

  • Prior splenectomy
  • Splenic irradiation within 3 months prior to the first dose of study drug
  • Eligible for allogeneic bone marrow or stem cell transplantation
  • Uncontrolled inter-current illness, per protocol.
  • Known positive status for (HIV)
  • Chronic active or acute viral hepatitis A, B, or C infection, or a or C carrier
  • Prior use of a JAK1 or JAK2 inhibitor
  • Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or therapy within 4 weeks of the first dose of study drug
  • Presence of peripheral neuropathy ≥ (CTCAE) Grade 2
  • Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    Momelotinib

    Participants will receive momelotinib plus placebo to match ruxolitinib.

    Drug: Momelotinib · Drug: Placebo to match ruxolitinib

  • Active comparator
    Ruxolitinib

    Participants will receive ruxolitinib plus placebo to match momelotinib.

    Drug: Ruxolitinib · Drug: Placebo to match momelotinib

Interventions

  • Momelotinib tablet administered orally once daily

    Also known as: GS-0387, CYT387

  • Ruxolitinib tablets administered orally twice daily

  • DrugPlacebo to match momelotinib

    Placebo to match momelotinib tablets administered orally once daily

  • DrugPlacebo to match ruxolitinib

    Placebo to match ruxolitinib tablets administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Splenic Response Rate at Week 24

    Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.

    Time frame: Week 24

Secondary outcomes

  1. Total Symptom Score (TSS) Response Rate at Week 24

    Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of the Total Symptom Score (TSS), in this study was based on 7 of these items, (range of 0-70,), excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 being the worse

    Time frame: Week 24

  2. Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)

    Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.

    Time frame: Baseline to Week 24

  3. RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)

    RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.

    Time frame: Week 24

  4. RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).

    RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding). Participants with the last double-blind phase participation date prior to Day 162 (ie. missing at Week 24) were considered transfusion dependent at Week 24.

    Time frame: Week 24

07

Results

Posted May 12, 2023

Participant flow

432 participants were randomized at 131 centers in 22 countries.

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneMomelotinib (MMB)Ruxolitinib (RUX)MMB to MMBRUX to MMB
Started21521700
Completed18820800
Not completed27900
Withdrew: Adverse event10400
Withdrew: Death5200
Withdrew: Physician decision5100
Withdrew: Subject decision4200
Withdrew: Disease progression2000
Withdrew: Symptomatic spleen growth1000
Open-label Phase
Participant flow — Open-label Phase
MilestoneMomelotinib (MMB)Ruxolitinib (RUX)MMB to MMBRUX to MMB
Started00171197
Completed0010
Not completed00170197
Withdrew: Transferred to study sra-mmb-4365005262
Withdrew: Adverse event003749
Withdrew: Disease progression002627
Withdrew: Lack of efficacy001719
Withdrew: Subject decision001415
Withdrew: Death001311
Withdrew: Physician decision00914
Withdrew: Non-compliance with study drug0020

Outcome measures

PrimarySplenic Response Rate at Week 24

Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Splenic Response Rate at Week 24
ParticipantsMomelotinib (MMB)Ruxolitinib (RUX)
Responder5764
Nonresponder158153
Statistical analysis
  • Momelotinib (MMB) vs Ruxolitinib (RUX) · Cochran-Mantel-Haenszel · p = 0.014 · Proportion difference - stratified cmh: 0.09 · 95% CI 0.02 to 0.16
SecondaryTotal Symptom Score (TSS) Response Rate at Week 24

Total symptom score (TSS) is defined as the percentage of participants who achieved a ≥50% reduction in TSS at Week 24 versus baseline as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) v2.0 diary. Response rate was calculated using the average of the daily TSS from a consecutive 28-day period prior to Week 24, which had ≥20 daily TSS available. The modified MPN-SAF patient-reported outcome instrument consisted of 8 items assessing worst daily incidence of tiredness, filling up quickly, abdominal discomfort, night sweats, itching, bone pain, pain under ribs on left side, and inactivity. Scoring of the Total Symptom Score (TSS), in this study was based on 7 of these items, (range of 0-70,), excluding inactivity. These items assess the impact experienced by the participant in the 24 hours prior to completing the questionnaire. All items are measured using a 0 to 10 Numeric Rating Scale, with 0 corresponding to "Absent" and 10 being the worse

Time frame:
Week 24
Reported as:
Count of participants · Participants
Total Symptom Score (TSS) Response Rate at Week 24
ParticipantsMomelotinib (MMB)Ruxolitinib (RUX)
Responder6089
Nonresponder151122
Statistical analysis
  • Momelotinib (MMB) vs Ruxolitinib (RUX) · Cochran-Mantel-Haenszel · p = 0.98 · Proportion difference - stratified cmh: 0.00 · 95% CI -0.08 to 0.08
SecondaryRate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)

Rate of RBC transfusion was defined as the average number of RBC units transfused not associated with clinically overt bleeding per subject-month during the double-blind phase.

Time frame:
Baseline to Week 24
Reported as:
Median · units/month
Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)
units/monthMomelotinib (MMB)Ruxolitinib (RUX)
Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding)0.0 (0.0 to 0.2)0.4 (0.0 to 1.5)
Statistical analysis
  • Momelotinib (MMB) vs Ruxolitinib (RUX) · Negative Binomial Model, Adjusted · p = <0.001 · Rate ratio: 0.28 · 95% CI 0.19 to 0.43A smaller ratio represents larger benefit.
SecondaryRBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)

RBC transfusion independence is the percentage of participants who are transfusion independent at Week 24, defined as absence of RBC transfusions and no hemoglobin level below 8 g/dL in the 12 weeks prior to Week 24, excluding cases associated with clinically overt bleeding.

Time frame:
Week 24
Reported as:
Count of participants · Participants
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding)
ParticipantsMomelotinib (MMB)Ruxolitinib (RUX)
Responder143107
Nonresponder72110
Statistical analysis
  • Momelotinib (MMB) vs Ruxolitinib (RUX) · Cochran-Mantel-Haenszel · p = <0.001 · Proportion difference - stratified cmh: 0.18 · 95% CI 0.09 to 0.26A larger proportion represents larger benefit.
SecondaryRBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).

RBC transfusion dependence is the percentage of participants who are transfusion dependent at Week 24, defined as having had at least 4 units of RBC transfusions, or a hemoglobin level below 8 g/dL in 8 weeks prior to Week 24 (excluding cases associated with clinically overt bleeding). Participants with the last double-blind phase participation date prior to Day 162 (ie. missing at Week 24) were considered transfusion dependent at Week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)).
ParticipantsMomelotinib (MMB)Ruxolitinib (RUX)
Dependent6587
Nondependent150130
Statistical analysis
  • Momelotinib (MMB) vs Ruxolitinib (RUX) · Cochran-Mantel-Haenszel · p = 0.019 · Proportion difference - stratified cmh: -0.10 · 95% CI -0.19 to -0.02A smaller proportion represents larger benefit.

Adverse events

Collected over Serious and other Adverse events were recorded that occurred from initiation of investigational product (IP) until 30 days after the last administration of IP regardless of cause or relationship. Serious events are monitored up to 12 weeks and all-cause mortality was assessed for up to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Momelotinib (MMB)8/214 (3.7%)49/214 (22.9%)197/214 (92.1%)
Ruxolitinib (RUX)6/216 (2.8%)39/216 (18.1%)206/216 (95.4%)
MMB to MMB44/171 (25.7%)79/171 (46.2%)153/171 (89.5%)
RUX to MMB54/197 (27.4%)79/197 (40.1%)188/197 (95.4%)
Most frequent serious events
Showing 10 of 233
Most frequent serious events
EventMomelotinib (MMB)Ruxolitinib (RUX)MMB to MMBRUX to MMB
PneumoniaInfections and infestations4/2143/21616/1719/197
AnaemiaBlood and lymphatic system disorders4/2148/2167/1714/197
SepsisInfections and infestations2/2141/2166/1711/197
Cardiac failureCardiac disorders2/2140/2165/1712/197
Urinary tract infectionInfections and infestations0/2142/2162/1715/197
ThrombocytopeniaBlood and lymphatic system disorders0/2143/2160/1714/197
Atrial fibrillationCardiac disorders4/2141/2163/1714/197
DiarrhoeaGastrointestinal disorders4/2141/2160/1714/197
Acute kidney injuryRenal and urinary disorders1/2141/2163/1714/197
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2140/2161/1714/197
Most frequent other events
Showing 10 of 46
Most frequent other events
EventMomelotinib (MMB)Ruxolitinib (RUX)MMB to MMBRUX to MMB
AnaemiaBlood and lymphatic system disorders30/21479/21638/17129/197
ThrombocytopeniaBlood and lymphatic system disorders40/21462/21629/17139/197
HeadacheNervous system disorders38/21443/21613/17124/197
NauseaGastrointestinal disorders33/2148/21616/17139/197
DiarrhoeaGastrointestinal disorders36/21442/21630/17137/197
FatigueGeneral disorders31/21426/21617/17138/197
CoughRespiratory, thoracic and mediastinal disorders18/21417/21623/17134/197
DizzinessNervous system disorders34/21425/21617/17125/197
Peripheral sensory neuropathyNervous system disorders20/21412/21615/17128/197
Abdominal painGastrointestinal disorders21/21424/21613/17126/197

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
<=18 years000
Between 18 and 65 years9095185
>=65 years125122247
Age, Continuous
Age, Continuous(years)Momelotinib (MMB)Ruxolitinib (RUX)Total
Median67 (28 to 85)66 (25 to 86)66 (25 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
Female9197188
Male124120244
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
Hispanic or Latino6410
Not Hispanic or Latino191194385
Unknown or Not Reported181937
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
White179178357
Black or African American224
Asian172037
Not Permitted151631
Other213
Transfusion Dependent
Transfusion Dependent(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
Yes5352105
No162165327
Platelet Count (10^9/L)
Platelet Count (10^9/L)(Participants)Momelotinib (MMB)Ruxolitinib (RUX)Total
< 100182341
>= 100 and <= 2006663129
> 200131131262
Weight
Weight(kg)Momelotinib (MMB)Ruxolitinib (RUX)Total
Median69.3 (62.9 to 80.0)71.4 (62.5 to 83.4)70.0 (62.8 to 82.0)

3 further baseline measures are reported on the registry.

08

Study locations

114 sites
  • Phoenix, Arizona, United States
  • Escondido, California, United States
  • Stanford, California, United States
  • Jacksonville, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Durham, North Carolina, United States
  • Seattle, Washington, United States
  • Darlinghurst, New South Wales, Australia
  • Parkville, New South Wales, Australia
  • Saint Leonards, New South Wales, Australia
  • Brisbane, Queensland, Australia
  • Herston, Queensland, Australia
  • Adelaide, South Australia, Australia
  • Bedford Park, South Australia, Australia
  • Frankston, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Perth, Western Australia, Australia
  • Wien, Vienna, Austria
  • Charleroi, Hainaut, Belgium
  • Antwerp, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Ruse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • Toronto, Ontario, Canada
  • Hradec Kralove, Vychodocesky KRAJ, Czechia
  • Brno, Czechia
  • Ostrava, Czechia
  • Aalborg, Denmark
  • Herlev, Denmark
  • Toulouse cedex 9, Midi-pyrenees, France
  • Pierre Bénite Cedex, Rhone-alpes, France
  • Le Kremlin Bicetre Cedex, France
  • Lens, France
  • Lille Cedex, France
  • Marseille Cedex 9, France
  • Nantes cedex 1, France
  • Paris, France
  • Pessac Cedex, France
  • Villejuif Cedex, France
  • München, Bayern, Germany
  • Leipzig, Sachsen, Germany
  • Dresden, Germany
  • Dusseldorf, Germany
  • Freiburg, Germany
  • Hamburg, Germany
  • Mainz, Germany
  • Mannheim, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Kaposvár, Hungary
  • Afula, Israel
  • Ashkelon, Israel
  • Haifa, Israel
  • Jerusalem, Israel
  • Tel Aviv, Israel
  • Ogaki City, Gifu, Japan
  • Kitaku Sapporo, Hokkaido, Japan
  • Osaka Sayama, Osaka, Japan
  • Osaka-City, Osaka, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Fukushima City, Japan
  • Kumamoto City, Japan
  • Matsuyama, Japan
  • Okayama, Japan
  • Seoul, Korea, Republic of
  • Maastricht, Netherlands
  • Nijmegen, Netherlands
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
  • Lodz, Lodzkie, Poland
  • Lublin, Lubelskie, Poland
  • Kraków, Malopolskie, Poland
  • Warszawa, Mazowiekie, Poland
  • Gdansk, Pomorskie, Poland
  • Poznan, Wielkopolskie, Poland
  • Bialystok, Poland
  • Brzozow, Poland
  • Chorzow, Poland
  • Arad, Romania
  • Brasov, Romania
  • Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Iasi, Romania
  • Singapore, Singapore
  • Majadahonda, Madrid, Spain
  • Pamplona, Navarra, Spain
  • Badalona, Spain
  • Barcelona, Spain
  • Valencia, Spain

Showing the first 100 of 114 sites across 22 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Sep 2016, 33 months.

Results were first posted in May 2023, 6 years 8 months after primary completion. A results delay was requested in Jan 2017.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 25, 2013
StartActual
Dec 6, 2013
Primary completionActual
Sep 12, 2016
CompletionActual
May 2, 2019
Results delay requested
Jan 5, 2017
Results first posted
May 12, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01969838
Responsible party
Sponsor
First posted
Oct 25, 2013
Start date
Dec 6, 2013
Primary completion
Sep 12, 2016
Completion
May 2, 2019
Results posted
May 12, 2023
Last update
May 12, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion